Home
 /
Papers
 /
Biochemistry
 /
De novo design of phosphotyrosine peptide binders
Preprint
Open access
V1
Top 1% · Validated by QED

De novo design of phosphotyrosine peptide binders

Magnus S Bauer, Jason Z Zhang, Kejia Wu +30 more
January 2026
 ·
bioRxiv
 ·
DOI 
10.1101/2025.09.29.678898
94
%
Reproducible
QED Impressions
This paper passed independent validation.
QED's automated review checked the evidence supporting each claim, the statistical methods, and whether the results are reproducible from the data provided.

It ranks in the top 1% of preprints assessed in Biochemistry this quarter.
Run full QED analysis
Read paper
Save

Why this is interesting

By establishing the first generative design framework for post-translationally modified proteins, this work makes phosphotyrosine signaling sites—previously inaccessible to computational design—precisely and selectively targetable, validated by crystallography and live-cell receptor tracking.

QED claims analysis

Summary

RFD2-MI, a deep generative framework for all-atom diffusion-based design, enables de novo generation of compact protein binders that recognize phosphotyrosine-containing peptides with sub-micromolar to low-micromolar affinities, phosphorylation and sequence specificity validated by crystal structures matching design models at sub-angstrom accuracy, and functional recognition of physiologically phosphorylated targets in living cells upon receptor activation.

See full analysis
Main Claim 1 –

RFD2-MI designs phosphotyrosine-specific peptide binders from sequence

Main Claim 2 –

Designed phosphotyrosine binders show sub-µM affinity and pY specificity

Supporting evidence

  • Crystal structures match designs with precise phosphate positioning
  • Designed phosphotyrosine binders are sequence-specific with minimal cross-reactivity
Main Claim 3 –

Designed binders recognize phosphorylated EGFR in cells after EGF

Supporting evidence

  • Cellular binder recruitment requires pY1068 and is kinase-dependent

Abstract

Phosphorylation on tyrosine is a key step in many signaling pathways. Despite recent progress in de novo design of protein binders, there are no current methods for designing binders that recognize phosphorylated proteins and peptides; this is a challenging problem as phosphate groups are highly charged, and phosphorylation often occurs within unstructured regions. Here we introduce RoseTTAFold Diffusion 2 for Molecular Interfaces (RFD2-MI), a deep generative framework for the design of binders for protein, ligand, and covalently modified protein targets. We demonstrate the power and versatility of this method by designing binders for four critical phosphotyrosine sites on three clinically relevant targets: Cluster of Differentiation 3 (CD3ε), Epidermal Growth Factor Receptor (EGFR), Insulin Receptor (INSR) and Signal Transducer and Activator of Transcription 5 (STAT5). Experimental characterization shows that the designs bind their phosphotyrosine containing targets with affinities comparable to native binding sites and have negligible binding to non-phosphorylated targets or phosphopeptides with different sequences. X-ray crystal structures of generated binders to CD3ε and EGFR are very close to the design models, demonstrating the accuracy of the design approach. A designed binder to an EGFR intracellular region phosphorylated upon EGF activation co-localizes with the receptor following EGF stimulation in single-particle tracking (SPT) experiments, demonstrating pY specific recognition in living cells. RFD2-MI provides a generalizable all-atom diffusion framework for probing and modulating phosphorylation-dependent signaling, and more generally, for developing research tools and targeted therapeutics against post-translationally modified proteins.

Related papers

How the QED Score works

QED Score is a validated AI-based quality metric that evaluates life science papers on two dimensions: originality and validity. Each manuscript is anonymized, broken down into its claims and supporting evidence, and examined by specialized AI agents for statistical rigor, consistency across figures, and fit with the existing literature. Scores are percentile ranks, so they're comparable across fields. In blinded tests, expert professors sided with QED Score over journal rank in 75% of decisive cases.
Read the methodology

Free access for academic researchers

Create your free QED account to validate your research, strengthen grant proposals, and uncover scientific insights.
We've sent you an access link.
Please check your inbox.

Didn't get your email? Check your spam folder or reach out to info@qedscience.com

Oops! Something went wrong while submitting the form.
Looking for QED for pharma, biotech or life science organizations?